This study aims to explore the efficacy and safety of scipibaimab combined with tislelizumab in patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed after first-line therapy.
1. Histologically or cytologically confirmed with recurrent or metastatic nasopharyngeal carcinoma which is not amenable to curative treatment with surgery and/or radiation therapy.
2. Age ≥ 18 years and ≤ 75 years, both genders.
3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
4. Life expectancy of at least 3 months.
1.Known history of hypersensitivity to any components of the Tislelizumab formulation, or other monoclonal antibody.
2.Prior therapy with any anti-interleukin-4 receptor α (IL-4Rα) monoclonal antibody, anti-IgE monoclonal antibody, or other monoclonal antibodies/biological agents.
3.There was a history of severe bleeding, and any bleeding events with a serious grade of 3 or more in CTCAE5.0 occurred within 4 weeks before screening.
4.Before treatment, MRI showed that the tumor may have invaded important blood vessels (such as enclosing the internal carotid artery / vein), nasopharyngeal necrosis, or researchers have determined that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during treatment.
Sun Yat-sen University
Lead sponsor
Sichuan Cancer Hospital and Research Institute
Collaborator
Cancer Hospital of Guangxi Medical University
Collaborator